# Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

> **NCT01574248** · PHASE4 · TERMINATED · sponsor: **Vanderbilt University Medical Center** · enrollment: 33 (actual)

## Conditions studied

- ACE Inhibitor-associated Angioedema

## Interventions

- **DRUG:** icatibant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01574248
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2015-09
- **Final completion:** 2016-02
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** DSMC recommended discontinuation for futility and feasibility
- **Last updated:** 2017-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01574248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01574248, "Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01574248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*